Cross-talk between mesenchymal stem/stromal cells and dendritic cells

Current Stem Cell Research and Therapy

Volumn 11, Issue 1, 2016, Pages 51-65

  Đokić, Jelena M ^a   Tomić, Sergej Z ^a   Čolić, Miodrag J ^a,b  

^a Serbia   (Serbia)

^b NONE   (Serbia)

Author keywords

Dendritic cells; Immunoregulation; Mesenchymal stem cells; Soluble mediators; Therapy; Tissue regeneration

Indexed keywords

CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; DENDRITIC CELL; HUMAN; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; ANIMAL; CELL COMMUNICATION; CELL MOTION; IMMUNITY; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOVEMENT; DENDRITIC CELLS; HUMANS; IMMUNITY; MESENCHYMAL STROMAL CELLS; SIGNAL TRANSDUCTION;

EID: 84959360077     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888x10666150904114035     Document Type: Review

References (185)

1. Yang M, Zhang H, Gangolli R. Advances of mesenchymal stemcells derived from bone marrow and dental tissue in craniofacial tissue engineering. Curr Stem Cell Res Ther 2014; 9: 150-61.
2. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesen-chymal stem cells: biological aspects and clinical applications. J Immunol Res 2015; 2015: 394917.
3. U.S. National Institutes of Health. Specialized Information Services: ClinicalTrials.gov https: //clinicaltrials.gov. Search for ‘‘mesenchymal stem cells’’ (Accessed May 26, 2015).
4. Bobis S, Jarocha D, Majka M. Mesenchymal stem cells: characteristics and clinical applications. Folia Histochem Cyto 2007; 44: 215-4.
5. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in healthand disease. Nat Rev Immunol 2008; 8: 726-36.
6. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two stepsforward, one step back. Trends Mol Med 2010; 16: 203-9.
7. Hass R, Kasper C, Bohm S, Jacobs R. Different populations andsources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 2011; 9: 12.
8. Huang GT, Gronthos S, Shi S. Mesenchymal stem cells derivedfrom dental tissues vs. those from other sources: their biology and role in regenerative medicine. J Dent Res 2009; 88: 792-806.
9. Wagner W, Horn P, Castoldi M, et al. Replicative senescence ofmesenchymal stem cells: a continuous and organized process. PLoS One 2008; 3: e2213.
10. Ikebe C, Suzuki K. Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int 2014; 2014: 951512.
11. Menard C, Pacelli L, Bassi G, et al. Clinical-grade mesenchymalstromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 2013; 22: 1789801.
12. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The developmentof fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970; 3: 393-403.
13. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-50.
14. Haque N, Kasim NH, Rahman MT. Optimization of pre-transplantation conditions to enhance the efficacy of mesenchymal stem cells. Int J Biol Sci 2015; 11: 324-34.
15. Riekstina U, Muceniece R, Cakstina I, Muiznieks I, Ancans J. Characterization of human skin-derived mesenchymal stem cell proliferation rate in different growth conditions. Cytotechnology 2008; 58: 153-62.
16. Jackson WM, Nesti LJ, Tuan RS. Potential therapeutic applicationsof muscle-derived mesenchymal stem and progenitor cells. Expert Opin Biol Ther 2010; 10: 505-17.
17. Najimi M, Khuu DN, Lysy PA, et al. Adult-derived human livermesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant 2007; 16: 717-28.
18. Fan J, Varshney RR, Ren L, Cai D, Wang DA. Synovium-derivedmesenchymal stem cells: a new cell source for musculoskeletal regeneration. Tissue Eng Part B Rev 2009; 15: 75-86.
19. Baertschiger RM, Bosco D, Morel P, et al. Mesenchymal stem cellsderived from human exocrine pancreas express transcription factors implicated in beta-cell development. Pancreas 2008; 37: 75-84.
20. Jarvinen L, Badri L, Wettlaufer S, et al. Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol 2008; 181: 4389-96.
21. In 't Anker PS, Scherjon SA, Kleijburg-van der Keur C, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 2003; 102: 1548-9.
22. Phinney DG. Functional heterogeneity of mesenchymal stem cells:implications for cell therapy. J Cell Biochem 2012; 113: 2806-12.
23. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria fordefining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
24. Sacchetti B, Funari A, Michienzi S, et al. Self-renewing osteopro-genitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324-36.
25. Gronthos S, Zannettino AC, Graves SE, et al. Differential cellsurface expression of the STRO 1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res 1999; 14: 47-56.
26. Battula VL, Treml S, Bareiss PM, et al. Isolation of functionallydistinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 2009; 94: 173-84.
27. Tomic S, Djokic J, Vasilijic S, et al. Immunomodulatory propertiesof mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists. Stem Cells Dev 2010; 20: 695-708.
28. oki J, Tomi S, Cerovi S, et al. Characterization and immuno-suppressive properties of mesenchymal stem cells from periapical lesions. J Clin Periodontol 2012; 39: 807-16.
29. Woodbury D, Reynolds K, Black IB. Adult bone marrow stromalstem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis. J Neurosci Res 2002; 69: 908-17.
30. Phinney DG, Prockop DJ. Concise review: mesenchymalstem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells 2007; 25: 2896902.
31. Jin HJ, Park SK, Oh W, et al. Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. Biochem Biophys Res Commun 2009; 381: 676-81.
32. Lee HJ, Choi BH, Min BH, Park SR. Changes in surface markersof human mesenchymal stem cells during the chondrogenic differentiation and dedifferentiation processes in vitro. Arthritis Rheum 2009; 60: 2325-32.
33. Krampera M. Mesenchymal stromal cell ‘licensing’: a multistepprocess. Leukemia 2011; 25: 1408-14.
34. Liotta F, Angeli R, Cosmi L, et al. Toll-like receptors 3 and 4 areexpressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26: 279-89.
35. Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinaseR. Stem Cells 2009; 27: 909-19.
36. Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-likereceptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-32.
37. Romieu-Mourez R, Francois M, Boivin MN, et al. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009; 182: 7963-73.
38. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A newmesenchymal stem cell (MSC) paradigm: polarization into a proinflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5: e10088.
39. Pistoia V, Raffaghello L. Damage-associated molecular patterns(DAMPs) and mesenchymal stem cells: a matter of attraction and excitement. Eur J Immunol 2011; 41: 1828-31.
40. Raicevic G, Najar M, Stamatopoulos B, et al. The source of humanmesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol 2011; 270: 207-16.
41. Lombardo E, DelaRosa O, Mancheño-Corvo P, et al. Toll-likeReceptor-Mediated Signaling in Human Adipose-Derived Stem Cells: Implications for Immunogenicity and Immunosuppressive Potential. Tissue Eng Part A 2008; 15: 1579-89.
42. Ma S, Xie N, Li W, et al. Immunobiology of mesenchymal stemcells. Cell Death Differ 2014; 21: 216-25.
43. Sallusto F, Lanzavecchia A. Efficient presentation of soluble anti-gen by cultured human dendritic cells is maintained by granulo-cyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-18.
44. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann Rev Immunol 2003; 21: 685-711.
45. Manz MG, Traver D, Miyamoto T, Weissman IL, Akashi K. Den-dritic cell potentials of early lymphoid and myeloid progenitors. Blood 2001; 97: 3333-41.
46. Caux C, Vanbervliet B, Massacrier C, et al. CD34+ hematopoieticprogenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+ TNF alpha. J Exp Med 1996; 184: 695-706.
47. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64.
48. Sanchez-Torres C, Garcia-Romo GS, Cornejo-Cortes MA, Rivas-Carvalho A, Sanchez-Schmitz G. CD16+ and CD16human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells. Int Immunol 2001; 13: 1571-81.
49. Geissmann F, Prost C, Monnet J-P, et al. Transforming growthfactor 1, in the presence of granulocyte/macrophage colonystimulating factor and interleukin 4, induces differentiation of human peripheral blood monocytes into dendritic Langerhans cells. J Exp Med 1998; 187: 961-6.
50. Strobl H, Riedl E, Scheinecker C, et al. TGF-beta 1 promotes invitro development of dendritic cells from CD34+ hemopoietic progenitors. J Immunol 1996; 157: 1499-507.
51. Rajkovic I, Dragicevic A, Vasilijic S, et al. Differences in T helperpolarizing capability between human monocyte derived dendritic cells and monocyte derived Langerhans’ like cells. Immunology 2011; 132: 217-25.
52. Mellman I, Steinman RM. Dendritic Cells-Specialized and Regu-lated Antigen Processing Machines. Cell 2001; 106: 255-8.
53. Bonasio R, von Andrian UH. Generation, migration and function ofcirculating dendritic cells. Curr Opin Immunol 2006; 18: 503-11.
54. Tisch R. Immunogenic versus tolerogenic dendritic cells: a matterof maturation. Int Rev Immunol 2010; 29: 111-8.
55. Hua D, Sun J, Mao Y, et al. B7-H1 expression is associated withexpansion of regulatory T cells in colorectal carcinoma. World J Gastroenterol 2012; 18: 971.
56. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science2000; 290: 84-9.
57. Vlad G, Chang CC, Colovai AI, et al. Membrane and soluble ILT3are critical to the generation of T suppressor cells and induction of immunological tolerance. Int Rev Immunol 2010; 29: 119-32.
58. Qu Y, Zhao Y. Regulatory CD4(+)CD25(+) T-cells are controlledby multiple pathways at multiple levels. Int Rev Immunol 2007; 26: 145-60.
59. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-55.
60. Reis e Sousa C. Activation of dendritic cells: translating innate intoadaptive immunity. Curr Opin Immunol 2004; 16: 21-5.
61. Tze LE, Horikawa K, Domaschenz H, et al. CD83 increases MHCII and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. J Exp Med 2011; 208: 149-65.
62. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kineticsof chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 1617-25.
63. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunologicalplaymakers. Nat Immunol 2012; 13: 722-8.
64. de Jong EC, Smits HH, Kapsenberg ML. Dendritic cell-mediated Tcell polarization. Springer Sem Immun 2005; 26: 289-307.
65. McGeachy MJ, Cua DJ. Th17 cell differentiation: the long andwinding road. Immunity 2008; 28: 445-53.
66. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mes-enchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-13.
67. Dokic J, Tomic S, Markovic M, Milosavljevic P, Colic M. Mesen-chymal stem cells from periapical lesions modulate differentiation and functional properties of monocyte-derived dendritic cells. Eur J Immunol 2013; 43: 1862-72.
68. Rüster B, Göttig S, Ludwig RJ, et al. Mesenchymal stem cellsdisplay coordinated rolling and adhesion behavior on endothelial cells. Blood 2006; 108: 3938-44.
69. Teo GS, Ankrum JA, Martinelli R, et al. Mesenchymal Stem CellsTransmigrate Between and Directly Through Tumor Necrosis Factor Activated Endothelial Cells Via Both Leukocyte Like and Novel Mechanisms. Stem Cells 2012; 30: 2472-86.
70. Randolph GJ, Ochando J, Partida-Sánchez S. Migration of den-dritic cell subsets and their precursors. Ann Rev Immunol 2008; 26: 293-316.
71. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cellsinhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-6.
72. Li YP, Paczesny S, Lauret E, et al. Human mesenchymal stem cellslicense adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol 2008; 180: 1598-608.
73. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-7.
74. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibitmonocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSCderived prostaglandin E2. Blood 2009; 113: 6576-83.
75. Zhang W, Ge W, Li C, et al. Effects of mesenchymal stem cells ondifferentiation, maturation, and function of human monocytederived dendritic cells. Stem Cells Dev 2004; 13: 263-71.
76. Ramasamy R, Fazekasova H, Lam EW, et al. Mesenchymal stemcells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83: 71-6.
77. Liu X, Ren S, Ge C, et al. Sca-1+Lin-CD117MesenchymalStem/Stromal Cells Induce the Generation of Novel IRF8Controlled Regulatory Dendritic Cells through Notch-RBP-J Signaling. J Immunol 2015; 194: 4298-308.
78. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stemcells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-32.
79. de Sá Silva F, Ramos RN, de Almeida DC, et al. MesenchymalStem Cells Derived from Human Exfoliated Deciduous Teeth (SHEDs) Induce Immune Modulatory Profile in Monocyte-Derived Dendritic Cells. PLoS One 2014; 9: e98050.
80. Van Den Berk LC, Roelofs H, Huijs T, et al. Cord blood mesen-chymal stem cells propel human dendritic cells to an intermediate maturation state and boost interleukin 12 production by mature dendritic cells. Immunology 2009; 128: 564-72.
81. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressiveproperties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88: 795806.
82. Chen HW, Chen HY, Wang LT, et al. Mesenchymal stem cellstune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol 2013; 190: 5065-77.
83. Jung YJ, Ju SY, Yoo ES, et al. MSC-DC interactions: MSC inhibitmaturation and migration of BM-derived DC. Cytotherapy 2007; 9: 451-8.
84. Zhang Y, Cai W, Huang Q, et al. Mesenchymal stem cells alleviatebacteria-induced liver injury in mice by inducing regulatory dendritic cells. Hepatology 2014; 59: 671-82.
85. Liu X, Qu X, Chen Y, et al. Mesenchymal stem/stromal cells in-duce the generation of novel IL-10-dependent regulatory dendritic cells by SOCS3 activation. J Immunol 2012; 189: 1182-92.
86. Liu WH, Liu JJ, Wu J, et al. Novel mechanism of inhibition ofdendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One 2013; 8: e55487.
87. Chiesa S, Morbelli S, Morando S, et al. Mesenchymal stem cellsimpair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci USA 2011; 108: 17384-9.
88. Cahill EF, Tobin LM, Carty F, Mahon BP, English K. Jagged-1 isrequired for the expansion of CD4(+) CD25(+) FoxP3(+) regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res Ther 2015; 6: 19.
89. Aldinucci A, Rizzetto L, Pieri L, et al. Inhibition of immune syn-apse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J Immunol 2010; 185: 5102-10.
90. Kimbrel EA, Kouris NA, Yavanian GJ, et al. Mesenchymal stemcell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev 2014.
91. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modu-late allogeneic immune cell responses. Blood 2005; 105: 1815-22.
92. Palucka KA, Taquet N, Sanchez-Chapuis F, Gluckman JC. Den-dritic cells as the terminal stage of monocyte differentiation. J Immunol 1998; 160: 4587-95.
93. Ocaña-Morgner C, Götz A, Wahren C, Jessberger R. SWAP-70restricts spontaneous maturation of dendritic cells. J Immunol 2013; 190: 5545-58.
94. Zhang B, Liu R, Shi D, et al. Mesenchymal stem cells induce ma-ture dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009; 113: 46-57.
95. Park M, Kim YH, Ryu JH, Woo SY, Ryu KH. Immune suppressiveeffects of tonsil-derived mesenchymal stem cells on mouse bonemarrow-derived dendritic cells. Stem Cells Int 2015; 2015: 106540.
96. Grazia Roncarolo M, Gregori S, Battaglia M, et al. Interleu-kin 10 secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50.
97. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25 naive T cells to CD4+ CD25+ regulatory T cells by TGFinduction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-86.
98. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress sys-temic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006; 212: 256-71.
99. Apetoh L, Quintana FJ, Pot C, et al. The aryl hydrocarbon receptorinteracts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 2010; 11: 854-61.
100. Awasthi A, Carrier Y, Peron JP, et al. A dominant function forinterleukin 27 in generating interleukin 10-producing antiinflammatory T cells. Nat Immunol 2007; 8: 1380-9.
101. H 17 cells by IL-27. Semin Immunol 2011; 23: 438-45.
102. Coli M, Gazivoda D, Majstorovi I, et al. Immunomodulatoryactivity of IL-27 in human periapical lesions. J Dent Res 2009; 88: 1142-7.
103. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25: 221-42.
104. Coli M, Gazivoda D, Vucevi D, et al. Regulatory T-cells in peri-apical lesions. J Dent Res 2009; 88: 997-1002.
105. English K, Ryan J, Tobin L, et al. Cell contact, prostaglandin E2and transforming growth factor beta 1 play non redundant roles in human mesenchymal stem cell induction of CD4+ CD25Highforkhead box P3+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-60.
106. van den Berk LC, Jansen BJ, Snowden S, et al. Cord Blood Mesen-chymal Stem Cells Suppress DC-T Cell Proliferation via Prostaglandin B2. Stem Cells Dev 2014.
107. Choi YS, Jeong JA, Lim DS. Mesenchymal stem cell-mediatedimmature dendritic cells induce regulatory T cell-based immunosuppressive effect. Immunol Invest 2012; 41: 214-29.
108. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymalstem cells alter antigen-presenting cell maturation and induce Tcell unresponsiveness. Blood 2005; 105: 2214-9.
109. Selleri S, Dieng MM, Nicoletti S, et al. Cord-blood-derived mesen-chymal stromal cells downmodulate CD4+ T-cell activation by inducing IL-10-producing Th1 cells. Stem Cells Dev 2012; 22: 1063-75.
110. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gammain the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-98.
111. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switchesthe differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1: 510-4.
112. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498-505.
113. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokinesand prostaglandins induce maturation of potent immunostimulatorydendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27: 3135-42.
114. 2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 2002; 20: A8-A22.
115. Mitani H, Katayama N, Araki H, et al. Activity of interleukin 6 inthe differentiation of monocytes to macrophages and dendritic cells. Br J Haematol 2000; 109: 288-95.
116. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of thedifferentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-91.
117. Deng Y, Yi S, Wang G, et al. Umbilical Cord-Derived Mesenchy-mal Stem Cells Instruct Dendritic Cells to Acquire Tolerogenic Phenotypes through the IL-6-Mediated Upregulation of SOCS1. Stem Cells Dev 2014.
118. Chen L, Zhang W, Yue H, et al. Effects of human mesenchymalstem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev 2007; 16: 719-31.
119. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect ofmesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-44.
120. Saraiva M, O'Garra A. The regulation of IL-10 production by im-mune cells. Nat Rev Immunol 2010; 10: 170-81.
121. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ. Psoriaticskin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol 1995; 154: 2668-77.
122. Förtsch D, Röllinghoff M, Stenger S. IL-10 converts human den-dritic cells into macrophage-like cells with increased antibacterial activity against virulent Mycobacterium tuberculosis. J Immunol 2000; 165: 978-87.
123. Richmond A, Thomas HG. Melanoma growth stimulatory activity:isolation from human melanoma tumors and characterization of tissue distribution. J Cell Biochem 1988; 36: 185-98.
124. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells asregulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
125. Wisniewski HG, Vilcek J. TSG-6: an IL-1/TNF-inducible proteinwith anti-inflammatory activity. Cytokine Growth Factor Rev 1997; 8: 143-56.
126. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improvemyocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
127. Szanto S, Bardos T, Gal I, Glant TT, Mikecz K. Enhanced neutro-phil extravasation and rapid progression of proteoglycan-induced arthritis in TSG-6-knockout mice. Arthritis Rheum 2004; 50: 3012-22.
128. Mindrescu C, Dias AA, Olszewski RJ, et al. Reduced susceptibilityto collagen-induced arthritis in DBA/1J mice expressing the TSG-6 transgene. Arthritis Rheum 2002; 46: 2453-64.
129. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NFB signaling in resident macrophages. Blood 2011; 118: 330-8.
130. Qi Y, Jiang D, Sindrilaru A, et al. TSG-6 released from intrader-mally injected mesenchymal stem cells accelerates wound healing and reduces tissue fibrosis in murine full-thickness skin wounds. J Invest Dermatol 2014; 134: 526-37.
131. Liu Y, Yin Z, Zhang R, et al. MSCs inhibit bone marrow-derivedDC maturation and function through the release of TSG-6. Biochem Biophys Res Commun 2014; 450: 1409-15
132. Lee RH, Yu JM, Foskett AM, et al. TSG-6 as a biomarker to pre-dict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci USA 2014; 111: 16766-71.
133. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cellfate control and signal integration in development. Science 1999; 284: 770-6.
134. Cheng P, Nefedova Y, Miele L, Osborne BA, Gabrilovich D. Notch signaling is necessary but not sufficient for differentiation of dendritic cells. Blood 2003; 102: 3980-8.
135. Cheng P, Gabrilovich D. Notch signaling in differentiation andfunction of dendritic cells. Immunol Res 2008; 41: 1-14.
136. Epstein FH, Blobe GC, Schiemann WP, Lodish HF. Role of trans-forming growth factor in human disease. N Engl J Med 2000; 342: 1350-8.
137. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immuno-suppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 2010; 1: 2.
138. Strobl H, Knapp W. TGF1 regulation of dendritic cells. MicrobesInfect 1999; 1: 1283-90.
139. Geissmann F, Revy P, Regnault A, et al. TGF1 prevents thenoncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162: 4567-75.
140. Stone TW, Darlington LG. Endogenous kynurenines as targets fordrug discovery and development. Nat Rev Drug Discov 2002; 1: 609-20.
141. Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Inducingthe tryptophan catabolic pathway, indoleamine 2, 3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood 2009; 114: 5062-70.
142. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metaboliccontrol of immune responses. Trends Immunol 2013; 34: 137-43.
143. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromalcells inhibit allogeneic T-cell responses by indoleamine 2,3dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619-21.
144. Ren G, Su J, Zhang L, et al. Species variation in the mechanisms ofmesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-62.
145. Mezrich JD, Fechner JH, Zhang X, et al. An interaction betweenkynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185: 3190-8.
146. Bessede A, Gargaro M, Pallotta MT, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 2014; 511: 184-90.
147. Platzer B, Richter S, Kneidinger D, et al. Aryl hydrocarbon recep-tor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol 2009; 183: 66-74.
148. Schulz VJ, van Roest M, Bol-Schoenmakers M, et al. Aryl hydro-carbon receptor activation affects the dendritic cell phenotype and function during allergic sensitization. Immunobiology 2013; 218: 1055-62.
149. Wei P, Hu GH, Kang HY, et al. An aryl hydrocarbon receptorligand acts on dendritic cells and T cells to suppress the Th17 response in allergic rhinitis patients. Lab Invest 2014; 94: 528-35.
150. Nguyen NT, Kimura A, Nakahama T, et al. Aryl hydrocarbonreceptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 2010; 107: 19961-6.
151. Ren G, Zhang L, Zhao X, et al. Mesenchymal stem cell-mediatedimmunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-50.
152. Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes prolif-eration and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004; 93: 1210-30.
153. Li H-X, Luo X, Liu R-X, Yang Y-J, Yang G-S. Roles of Wnt/ -catenin signaling in adipogenic differentiation potential of adiposederived mesenchymal stem cells. Mol Cell Endocrinol 2008; 291: 116-24.
154. Bergenfelz C, Medrek C, Ekström E, et al. Wnt5a induces a tolero-genic phenotype of macrophages in sepsis and breast cancer patients. J Immunol 2012; 188: 5448-58.
155. Neumann J, Schaale K, Farhat K, et al. Frizzled1 is a marker ofinflammatory macrophages, and its ligand Wnt3a is involved in reprogramming Mycobacterium tuberculosis-infected macrophages. The FASEB Journal 2010; 24: 4599-612.
156. Zhou J, Cheng P, Youn J-I, Cotter MJ, Gabrilovich DI. Notch andwingless signaling cooperate in regulation of dendritic cell differentiation. Immunity 2009; 30: 845-59.
157. Manicassamy S, Reizis B, Ravindran R, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 2010; 329: 849-53.
158. Oderup C, LaJevic M, Butcher EC. Canonical and noncanonicalWnt proteins program dendritic cell responses for tolerance. J Immunol 2013; 190: 6126-34.
159. Salazar KD, Lankford SM, Brody AR. Mesenchymal stem cellsprocollagen expression by lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1002-L11.
160. Mougiakakos D, Jitschin R, Johansson CC, et al. The impact ofinflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117: 4826-35.
161. Nasef A, Mazurier C, Bouchet S, et al. Leukemia inhibitory factor:Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 2008; 253: 16-22.
162. Stubbendorff M, Deuse T, Hua X, et al. Immunological propertiesof extraembryonic human mesenchymal stromal cells derived from gestational tissue. Stem Cells Dev 2013; 22: 2619-29.
163. Foti M, Granucci F, Aggujaro D, et al. Upon dendritic cell (DC)activation chemokines and chemokine receptor expression are rapidly regulated for recruitment and maintenance of DC at the inflammatory site. Int Immunol 1999; 11: 979-86.
164. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2ainduces IP-10/CXCL10 and MIG/CXCL9 production in monocytederived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002; 71: 669-76.
165. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinatedswitch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28: 2760-9.
166. Ponte AL, Marais E, Gallay N, et al. The in vitro migration capac-ity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25: 1737-45.
167. Pablos JL, Amara A, Bouloc A, et al. Stromal-cell derived factor isexpressed by dendritic cells and endothelium in human skin. Am J Pathol 1999; 155: 1577-86.
168. Son BR, Marquez-Curtis LA, Kucia M, et al. Migration of bonemarrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006; 24: 1254-64.
169. Xie J, Wang W, Si JW, et al. Notch signaling regulates CXCR4expression and the migration of mesenchymal stem cells. Cell Immunol 2013; 281: 68-75.
170. Vulcano M, Albanesi C, Stoppacciaro A, et al. Dendritic cells as amajor source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 2001; 31: 812-22.
171. Smith H, Whittall C, Weksler B, Middleton J. Chemokines stimu-late bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells Dev 2012; 21: 476-86.
172. Guihard P, Danger Y, Brounais B, et al. Induction of osteogenesisin mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells 2012; 30: 762-72.
173. Nicolaidou V, Wong MM, Redpath AN, et al. Monocytes induceSTAT3 activation in human mesenchymal stem cells to promote osteoblast formation. PLoS One 2012; 7: e39871.
174. Erices A, Conget P, Rojas C, Minguell JJ. Gp130 activation bysoluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res 2002; 280: 24-32.
175. Ding J, Ghali O, Lencel P, et al. TNFand IL-1 inhibit RUNX2and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. Life Sci 2009; 84: 499-504.
176. Ghali O, Chauveau C, Hardouin P, Broux O, Devedjian JC. TNF 's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res 2010; 25: 1616-26.
177. De Keijzer S, Meddens MB, Torensma R, Cambi A. The MultipleFaces of Prostaglandin E2 G-Protein Coupled Receptor Signaling during the Dendritic Cell Life Cycle. Int J Mol Sci 2013; 14: 6542-55.
178. Arikawa T, Omura K, Morita I. Regulation of bone morphogeneticprotein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 2004; 200: 400-6.
179. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O.HLA expression and immunologic propertiesof differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003; 31: 890-6.
180. Liu H, Kemeny DM, Heng BC, et al. The immunogenicity and immunomodulatory function of osteogenic cells differentiated frommesenchymal stem cells. J Immunol 2006; 176: 2864-71.
181. Tuli R, Tuli S, Nandi S, et al. Transforming growth factor-betamediated chondrogenesis of human mesenchymal progenitor cellsinvolves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem 2003; 278: 41227-36.
182. Xu C, Yu P, Han X, et al. TGFpromotes immune responses in the presence of mesenchymal stem cells. J Immunol 2014; 192:103-9.
183. Croitoru-Lamoury J, Lamoury FM, Caristo M, et al. Interferonregulates the proliferation and differentiation of mesenchymal stemcells via activation of indoleamine 2, 3 dioxygenase (IDO). PLoS One 2011; 6: e14698.
184. Moretto MM, Weiss LM, Combe CL, Khan IA. IFN-producing dendritic cells are important for priming of gut intraepithelial lym-phocyte response against intracellular parasitic infection. J Immunol 2007; 179: 2485-92.
185. Kadowaki N, Antonenko S, Lau JY-N, Liu Y-J. Natural interferon /-producing cells link innate and adaptive immunity. J Exp Med2000; 192: 219-26.